Molecular Imaging Of Cancers With Copper And Zirconium Radiopharmaceuticals
Funder
National Health and Medical Research Council
Funding Amount
$466,475.00
Summary
This research aims to develop new imaging agents to assist in the diagnosis of breast cancer. This research will advance knowledge in the areas of chemistry, biotechnology and diagnostic imaging.
The Development Of Innovative Multiplexed Molecular Imaging Technology Targeting Improved Diagnostic Imaging Of Glioblastoma Multiforme
Funder
National Health and Medical Research Council
Funding Amount
$403,599.00
Summary
Glioblastoma Multiforme (GBM) is extremely invasive and the most lethal of all primary brain tumours. To optimise treatment planning, we propose to develop novel Multiplexed Molecular Imaging (MMI) technology employing the latest PET-MRI hybrid imaging technology. Our strategy targets the development of new F19 MRI MI agents for measuring tumour infiltration that can be multiplexed with F18 PET hypoxia tracers. Our MI agents can also act as conjugative vehicles for drug delivery.
The Australian, Imaging, Biomarkers And Lifestyle Study Of Ageing (AIBL) Phase III - Facilitating Early Intervention In Preclinical Alzheimer's Disease.
Funder
National Health and Medical Research Council
Funding Amount
$733,653.00
Summary
Amyloid brain scans can detect the onset of Alzheimer's disease 10-15 years before symptoms first appear. Amyloid build-up is thought to be the cause of Alzheimer's disease. The earlier that drugs designed to slow the build up of amyloid or to clear it from the brain are given, the greater the chance of benefit. This study will use the recent discoveries from the Australian AIBL study to develop the best method to find these people with brain amyloid but no symptoms for early treatment trials to ....Amyloid brain scans can detect the onset of Alzheimer's disease 10-15 years before symptoms first appear. Amyloid build-up is thought to be the cause of Alzheimer's disease. The earlier that drugs designed to slow the build up of amyloid or to clear it from the brain are given, the greater the chance of benefit. This study will use the recent discoveries from the Australian AIBL study to develop the best method to find these people with brain amyloid but no symptoms for early treatment trials to prevent dementia.Read moreRead less
Investigating Neuroinflammation And Its Relationship With Progressive Brain Structural Loss In Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$466,252.00
Summary
This project will investigate whether brain inflammation contributes to progressive brain volume loss in people with schizophrenia. Using novel brain scanning we will index whether brain cells involved in inflammation, called microglia, are in an activated state in people with schizophrenia. We expect microglia will be ‘activated’ in a subgroup of patients with schizophrenia, and will be related to progressive brain volume loss in these patients. This information will help us develop new treatme ....This project will investigate whether brain inflammation contributes to progressive brain volume loss in people with schizophrenia. Using novel brain scanning we will index whether brain cells involved in inflammation, called microglia, are in an activated state in people with schizophrenia. We expect microglia will be ‘activated’ in a subgroup of patients with schizophrenia, and will be related to progressive brain volume loss in these patients. This information will help us develop new treatments to prevent brain volume loss in the illness.Read moreRead less
Novel Radioligands For PET Imaging And Phenotyping Of Multiple Sclerosis Diagnosis
Funder
National Health and Medical Research Council
Funding Amount
$817,828.00
Summary
This project aims to catalyse a paradigm shift in the management of multiple sclerosis (MS). We will achieve this paradigm shift by developing radioligands that can be used to image the brain of MS patients. These agents will target a protein in MS patients that will be diagnostic of the state of disease progression. This will facilitate prediction of disease outcome, monitoring of therapeutic response and the development of novel treatment strategies for the better treatment of MS.
Use of antibodies for cancer therapy, where a protein is made in the laboratory to recognize and act on cancer cells that have a target antigen, has emerged as an important therapeutic area in oncology. The lewis-y (Ley) antigen is found on more than 70% of epithelial cancers and the A33 antigen is found on colon cancers. We have developed antibodies against Ley (hu3S193) and A33 (huA33) which can target cancer cells. We aim to develop optimal cancer cell killing by our antibodies.
A Combined PET-fMRI Study Of Frontostriatal Dysfunction In First Episode Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$872,873.00
Summary
Psychosis is a debilitating psychiatric syndrome affecting a person’s ability to understand reality. This project will map how disruptions of specific brain circuits give rise to psychosis, and how they relate to changes in the level of a specific brain chemical, dopamine, which is targeted by antipsychotic medications. This work has important implications for developing new, more targeted treatments.
Traumatic Brain Injury, Post Traumatic Stress Disorder And The Risk Of Neurodegenerative Disease: A Study Of Tau And Beta-amyloid Accumulation, Brain Structure And Function Several Decades After Injury.
Funder
National Health and Medical Research Council
Funding Amount
$1,076,860.00
Summary
The study aims to better understand the association between traumatic brain injury (TBI), post traumatic stress disorder (PTSD) and dementia, specifically Alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE). The study will examine retired AFL players, road trauma victims and Vietnam veterans with advanced imaging using PET brain scans for the abnormal brain deposits typical of AD and CTE and assess the risk of later developing these diseases from head injury and PTSD.
A Prospective Clinical Trial To Establish The Significance Of Interim FDG And FLT PET/CT Scans As Biomarkers Of Patient Prognosis And Individualised Radiation Therapy In Non-small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$532,902.00
Summary
Positron Emission Tomography (PET)/Computed Tomography (CT) scanners pinpoint the location of cancer cells in people prior to and after treatment. This innovative study will use during treatment PET/CT scans to establish the response of lung tumours to radiation therapy (RT). We will use these scans to simulate the delivery of highly targeted, individualised RT and to predict patient prognosis, with the ultimate aim of increasing survival and minimising side effects in patients with lung cancer
Novel 18F And 64Cu Labelled Targeted Nanoparticles For Molecular Positron Emission Tomography: A Means For Early And Sensitive Detection Of Thrombosis, Inflammation And Vulnerable, Rupture-prone Atherosclerotic Plaques
Funder
National Health and Medical Research Council
Funding Amount
$572,931.00
Summary
The aim of this project is to develop novel targeted positron emission tomography imaging agents that seek out specific markers for various states of cardiovascular disease. These agents would provide a method for detecting the presence and level of atherosclerosis and thrombotic events. The targeted nanoparticles may provide a unique opportunity to detect very early plaques and the vulnerability of existing plaques.